Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate

Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned

(2018) Eugene O Major et al.   LANCET NEUROLOGY

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis

(2018) Martijn T. Wijburg et al.   JAMA Neurology

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort

(2018) Martijn T Wijburg et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution

(2018) Cristina Scarpazza et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – NO

(2017) Christian Enzinger   Multiple Sclerosis Journal

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – Commentary

(2017) Mike P Wattjes et al.   Multiple Sclerosis Journal

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – YES

(2017) Siew Mei Yap et al.   Multiple Sclerosis Journal

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – NO

(2017) Christian Enzinger   Multiple Sclerosis Journal

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – Commentary

(2017) Mike P Wattjes et al.   Multiple Sclerosis Journal

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – YES

(2017) Siew Mei Yap et al.   Multiple Sclerosis Journal

Classifying PML risk with disease modifying therapies

(2017) Joseph R. Berger   Multiple Sclerosis and Related Disorders

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance

(2016) Martijn T Wijburg et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging

(2016) Jérôme Hodel et al.   RADIOLOGY

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry

(2016) Luca Prosperini et al.   PLoS One

Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis

(2015) A. Traboulsee et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy

(2015) Tuan Dong-Si et al.   JOURNAL OF NEUROVIROLOGY

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Clemens Warnke et al.   ANNALS OF NEUROLOGY

Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI

(2014) Mike P. Wattjes et al.   CURRENT OPINION IN NEUROLOGY

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

(2014) Mike P. Wattjes et al.   JOURNAL OF NEUROLOGY

MRI pattern in asymptomatic natalizumab-associated PML

(2014) Mike P Wattjes et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

(2014) Tuan Dong-Si et al.   Annals of Clinical and Translational Neurology

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

Presymptomatic Diagnosis with MRI and Adequate Treatment Ameliorate the Outcome after Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2013) Hans Lindå et al.   Frontiers in Neurology

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy

(2012) Tarek A. Yousry et al.   ANNALS OF NEUROLOGY

Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab

(2012) Eavan M. Mc Govern et al.   JOURNAL OF NEUROLOGY

Value of MRI as a surrogate marker for PML in natalizumab long-term therapy

(2012) I. Ayzenberg et al.   JOURNAL OF NEUROLOGY

Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance

(2012) N. F. Blair et al.   NEUROLOGY

The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?

(2012) R. Phan-Ba et al.   NEUROLOGY

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy: Figure 1

(2011) Rémy Phan-Ba et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Myopic Discounting of Future Rewards after Medial Orbitofrontal Damage in Humans

(2010) M. Sellitto et al.   JOURNAL OF NEUROSCIENCE

Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy

(2009) Patricia K Coyle et al.   Multiple Sclerosis Journal

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

(2009) Peter C. Austin   STATISTICS IN MEDICINE

An evaluation of traditional and novel tools for lesion behavior mapping

(2008) C RORDEN et al.   NEUROIMAGE